These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 17589426)

  • 1. Faster publication isn't always better.
    Fuster V; Farkouh ME
    Nat Clin Pract Cardiovasc Med; 2007 Jul; 4(7):345. PubMed ID: 17589426
    [No Abstract]   [Full Text] [Related]  

  • 2. The rosigliazone meta-analysis: lessons for the future.
    Shuster JJ; Schatz DA
    Diabetes Care; 2008 Mar; 31(3):e10. PubMed ID: 18308673
    [No Abstract]   [Full Text] [Related]  

  • 3. The rosiglitazone meta-analysis.
    McCullough PA; Lepor NE
    Rev Cardiovasc Med; 2007; 8(2):123-6. PubMed ID: 17603430
    [No Abstract]   [Full Text] [Related]  

  • 4. Outlook on diabetes drug less than rosy. Early work suggests that rosiglitazone (Avandia) may not be best for the heart.
    Harv Heart Lett; 2007 Aug; 17(12):1-2. PubMed ID: 17717888
    [No Abstract]   [Full Text] [Related]  

  • 5. [Rosiglitazone--statistics for benefits and problems].
    Hjelmesaeth J; Røislien J
    Tidsskr Nor Laegeforen; 2007 Oct; 127(20):2702-3. PubMed ID: 17952157
    [No Abstract]   [Full Text] [Related]  

  • 6. The Avandia debate: an unhappy conclusion.
    Bloomgarden Z; Handelsman Y
    J Diabetes; 2010 Dec; 2(4):221-2. PubMed ID: 20923505
    [No Abstract]   [Full Text] [Related]  

  • 7. Pioglitazone and the risk of myocardial infarction and other major adverse cardiac events: a meta-analysis of randomized, controlled trials.
    Nagajothi N; Adigopula S; Balamuthusamy S; Velazquez-Cecena JL; Raghunathan K; Khraisat A; Singh S; Molnar J; Khosla S; Benatar D
    Am J Ther; 2008; 15(6):506-11. PubMed ID: 19127132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The record on rosiglitazone and the risk of myocardial infarction.
    Psaty BM; Furberg CD
    N Engl J Med; 2007 Jul; 357(1):67-9. PubMed ID: 17551162
    [No Abstract]   [Full Text] [Related]  

  • 9. Controversy over the cardiovascular effects of thiazolidinediones.
    Kapoor JR
    Am J Med; 2008 Apr; 121(4):e9. PubMed ID: 18374677
    [No Abstract]   [Full Text] [Related]  

  • 10. Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone.
    Dahabreh IJ; Economopoulos K
    Clin Trials; 2008; 5(2):116-20. PubMed ID: 18375649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analytical issues regarding rosiglitazone meta-analysis.
    Claggett B; Wei LJ
    Arch Intern Med; 2011 Jan; 171(2):179-80; author reply 180. PubMed ID: 21263111
    [No Abstract]   [Full Text] [Related]  

  • 12. Rosiglitazone: a thunderstorm from scarce and fragile data.
    Mulrow CD; Cornell J; Localio AR
    Ann Intern Med; 2007 Oct; 147(8):585-7. PubMed ID: 17938398
    [No Abstract]   [Full Text] [Related]  

  • 13. Rosiglitazone and cardiovascular risk.
    Mannucci E; Monami M; Marchionni N
    N Engl J Med; 2007 Aug; 357(9):938; author reply 939-40. PubMed ID: 17806136
    [No Abstract]   [Full Text] [Related]  

  • 14. Cardiac safety profile of rosiglitazone: a comprehensive meta-analysis of randomized clinical trials.
    Mannucci E; Monami M; Di Bari M; Lamanna C; Gori F; Gensini GF; Marchionni N
    Int J Cardiol; 2010 Aug; 143(2):135-40. PubMed ID: 19328563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rosiglitazone and cardiovascular risk.
    Psaty BM; Furberg CD
    N Engl J Med; 2007 Jun; 356(24):2522-4. PubMed ID: 17517854
    [No Abstract]   [Full Text] [Related]  

  • 16. Setting the RECORD Straight.
    Nissen SE
    JAMA; 2010 Mar; 303(12):1194-5. PubMed ID: 20332408
    [No Abstract]   [Full Text] [Related]  

  • 17. Rosiglitazone and cardiovascular disease: a cardiologist's perspective.
    Marx N
    Diab Vasc Dis Res; 2007 Jun; 4(2):80-1. PubMed ID: 17654439
    [No Abstract]   [Full Text] [Related]  

  • 18. Rosiglitazone and cardiovascular risk.
    Diamond GA; Kaul S
    N Engl J Med; 2007 Aug; 357(9):938-9; author reply 939-40. PubMed ID: 17806135
    [No Abstract]   [Full Text] [Related]  

  • 19. The cardiovascular safety of diabetes drugs--insights from the rosiglitazone experience.
    Hiatt WR; Kaul S; Smith RJ
    N Engl J Med; 2013 Oct; 369(14):1285-7. PubMed ID: 23992603
    [No Abstract]   [Full Text] [Related]  

  • 20. The Avandia debate.
    Bloomgarden ZT
    Diabetes Care; 2007 Sep; 30(9):2401-8. PubMed ID: 17726191
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.